Brokerages Set bluebird bio, Inc. (NASDAQ:BLUE) PT at $51.00

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have received a consensus recommendation of “Hold” from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $51.00.

Several research analysts recently issued reports on the company. Wells Fargo & Company cut their price objective on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a research report on Monday, February 24th. JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Barclays increased their price objective on bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, December 31st. StockNews.com assumed coverage on shares of bluebird bio in a research note on Friday. They issued a “sell” rating for the company. Finally, Baird R W cut shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BLUE. Geode Capital Management LLC grew its holdings in bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after purchasing an additional 166,771 shares during the period. State Street Corp grew its stake in shares of bluebird bio by 1.1% during the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after buying an additional 43,382 shares during the period. FMR LLC increased its holdings in shares of bluebird bio by 8.1% during the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after buying an additional 186,903 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after buying an additional 355,562 shares during the period. Finally, Barclays PLC boosted its holdings in bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 184,605 shares during the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Price Performance

bluebird bio stock opened at $4.08 on Friday. The firm has a market capitalization of $39.67 million, a PE ratio of -0.11 and a beta of 0.76. bluebird bio has a 52 week low of $3.56 and a 52 week high of $28.60. The firm’s 50-day simple moving average is $5.53 and its 200 day simple moving average is $7.73. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.